A massive review from Purdue University concludes that deliberate administration of lipopolysaccharide (LPS)—a purified bacterial endotoxin—into healthy volunteers is, by and large, remarkably safe. The findings could influence how researchers design controlled inflammation studies used to probe immune pathways and test candidate therapies. The review focuses on LPS as an experimental inflammatory trigger, helping clarify risk expectations and the extent of adverse events across study designs. Controlled human models can reduce confounding versus observational approaches but depend critically on safety characterizations. For biotech and translational teams, improved clarity on safety profiles can support more efficient early-stage development of anti-inflammatory drugs, immunomodulators and vaccines by enabling reproducible immune activation. The work also supports continuing refinement of protocols around dosing, monitoring and inclusion criteria—key determinants of safety in challenge studies.